TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved the first generic version of a once-weekly estradiol-levonorgestrel patch for postmenopausal women with an intact uterus. It is indicated for moderate to severe hot flashes and prevention of osteoporosis, but carries significant contraindications, potential side effects and boxed warnings.
The U.S. Food and Drug Administration on Monday approved the first generic version of a once-weekly estradiol-levonorgestrel patch for postmenopausal women with an intact uterus, opening another option for treating moderate to severe vasomotor symptoms and preventing osteoporosis. The generic is equivalent to Climara Pro, according to the FDA announcement reported by MedPage Today.
The transdermal system supplies 0.045 milligrams of estradiol and 0.015 milligrams of levonorgestrel each day. Estradiol is an estrogen; levonorgestrel is a progestogen. The FDA said the progestogen is included to reduce the risk of endometrial hyperplasia, a thickening of the uterine lining that can occur with estrogen use alone.
The treatment is indicated for postmenopausal women who have an intact uterus. Its approved uses are relief of moderate to severe vasomotor symptoms, such as hot flashes, and prevention of osteoporosis. The source report does not identify the generic manufacturer, product name, price, availability date or expected cost compared with the brand-name patch.
FDA Center for Drug Evaluation and Research director Michael Davis said the weekly schedule could be convenient for patients. The agency’s statement described the patch as an alternative to daily oral medication; it did not provide evidence in the source material that the generic improves adherence or outcomes.
A Weekly Option With Key Safety Limits
The approval adds a generic choice in a treatment category used for menopause-related symptoms and osteoporosis prevention. A once-weekly patch may appeal to patients who prefer a transdermal treatment or find daily pills difficult to manage, although the FDA statement characterized convenience as a potential benefit rather than a proven improvement in treatment adherence.
Generic approval can increase competition, but its practical effect on availability and out-of-pocket costs is not yet established by the information provided. The treatment also is not suitable for everyone: the approval does not remove the product’s contraindications or the need for a clinician to weigh individual risks and benefits.
estradiol-levonorgestrel hormone patch
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Combination Patch Is Used
The patch combines estrogen with a progestogen for people who have a uterus. The FDA noted that levonorgestrel is included to reduce the risk of endometrial hyperplasia associated with estrogen alone. The approval concerns a generic of the existing Climara Pro system, not a new hormone combination or a new indication.
The report says the approval follows recent endorsements from the American College of Obstetricians and Gynecologists and the American College of Physicians for menopausal symptom care. It does not detail those endorsements or say they specifically recommended this patch. Separately, the FDA recently announced plans to remove boxed warnings from a number of hormone therapy products for menopausal symptoms; the report does not say those changes have taken effect for this product.
“Once-weekly dosing can make a real difference in how patients manage their care.”
— Michael Davis, director of the FDA’s Center for Drug Evaluation and Research
Availability and Label Changes Remain Open
The source report does not name the generic’s manufacturer or specify when pharmacies can obtain it. It also provides no pricing, insurance coverage or comparative cost information, so the effect of the approval on patients’ expenses is not yet clear.
The patch’s prescribing information carries a boxed warning about risks of cardiovascular disorders, probable dementia, breast cancer and endometrial cancer, based on findings from the Women’s Health Initiative. The FDA has announced plans to drop boxed warnings from a number of hormone therapy products, but the report does not confirm whether or when this product’s label will change. The source also does not provide details about the evidence or regulatory steps behind the planned changes.
The FDA lists the patch as contraindicated for people with undiagnosed abnormal genital bleeding; known or suspected breast cancer; estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism or arterial thromboembolic disease; liver impairment; or known thrombophilic disorders, including protein C, protein S or antithrombin deficiency. Reported common adverse events, occurring in 5% or more of patients, include application-site reactions, vaginal bleeding, upper respiratory infection, breast, back or general pain, depression, headache and flu-like syndrome. The source does not give event rates for each effect or comparative safety data for the generic.
Watch for Label and Supply Updates
Patients and clinicians will need to look for further information from the FDA and the generic manufacturer on product availability, labeling and pricing. Any change to the boxed warning should be confirmed through an updated FDA-approved prescribing label rather than inferred from the agency’s broader announcement about hormone therapy products.
People considering the patch should discuss whether its approved uses and risks fit their medical history with a health professional. The available report confirms the approval, but does not establish how quickly the generic will reach pharmacies or how widely it will be prescribed.
Key Questions
What did the FDA approve?
The FDA approved the first generic version of the once-weekly estradiol-levonorgestrel transdermal system sold as Climara Pro.
Who is the patch indicated for?
It is indicated for postmenopausal women with an intact uterus to treat moderate to severe vasomotor symptoms and prevent osteoporosis. A clinician can determine whether it is appropriate for an individual patient.
What hormones and doses does it deliver?
The patch delivers 0.045 mg of estradiol and 0.015 mg of levonorgestrel daily. The progestogen is included to reduce the risk of endometrial hyperplasia associated with estrogen use alone.
Does the approval mean the boxed warning has been removed?
No. The report says the product’s prescribing information still carries boxed warnings about cardiovascular disorders, probable dementia, breast cancer and endometrial cancer. The FDA has announced plans to remove warnings from a number of hormone therapy products, but a change to this patch’s label is not confirmed in the report.
When will the generic be available and how much will it cost?
The source report does not provide a launch date, manufacturer or price. Availability and the effect on patient costs remain unknown.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
